Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 476

1.

Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects.

Dietrich M, Aktas O, Hartung HP, Albrecht P.

Curr Opin Neurol. 2019 Jan 28. doi: 10.1097/WCO.0000000000000675. [Epub ahead of print]

PMID:
30694926
2.

Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats.

Dietrich M, Hecker C, Hilla A, Cruz-Herranz A, Hartung HP, Fischer D, Green A, Albrecht P.

J Vis Exp. 2019 Jan 10;(143). doi: 10.3791/58571.

PMID:
30688311
3.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Jan 22. doi: 10.1111/jns.12302. [Epub ahead of print]

PMID:
30672091
4.

Restabilization treatment after IVIG withdrawal in chronic inflammatory demyelinating polyneuropathy. Results from the pre-randomization phase of the Polyneuropathy and Treatment with Hizentra® (PATH) study.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group.

J Peripher Nerv Syst. 2019 Jan 22. doi: 10.1111/jns.12303. [Epub ahead of print]

PMID:
30672067
5.

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders.

Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.

Lancet Neurol. 2019 Feb;18(2):185-197. doi: 10.1016/S1474-4422(18)30460-5. Review.

PMID:
30663608
6.

Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study.

Hartung HP, Graf J, Kremer D.

J Neurol. 2019 Jan 4. doi: 10.1007/s00415-018-09169-w. [Epub ahead of print] Review.

PMID:
30610426
7.

Managing Risks with Immune Therapies in Multiple Sclerosis.

Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Mares J, Hartung HP, Kremer D.

Drug Saf. 2019 Jan 3. doi: 10.1007/s40264-018-0782-8. [Epub ahead of print] Review.

PMID:
30607830
8.

Monoclonal Antibodies for Multiple Sclerosis: An Update.

Graf J, Aktas O, Rejdak K, Hartung HP.

BioDrugs. 2019 Feb;33(1):61-78. doi: 10.1007/s40259-018-0327-9. Review.

PMID:
30604390
9.

Secretome analysis of nerve repair mediating Schwann cells reveals Smad-dependent trophism.

Schira J, Heinen A, Poschmann G, Ziegler B, Hartung HP, Stühler K, Küry P.

FASEB J. 2018 Dec 28:fj201801799R. doi: 10.1096/fj.201801799R. [Epub ahead of print]

PMID:
30592632
10.

High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.

Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Aktas O, Hartung HP, Hefter H.

Neurology. 2019 Jan 1;92(1):e48-e54. doi: 10.1212/WNL.0000000000006688. Epub 2018 Nov 21.

PMID:
30464031
11.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
12.

Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination.

Göttle P, Förster M, Gruchot J, Kremer D, Hartung HP, Perron H, Küry P.

Glia. 2019 Jan;67(1):160-170. doi: 10.1002/glia.23535. Epub 2018 Nov 14.

PMID:
30430656
13.

Racial differences in neuromyelitis optica spectrum disorder.

Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ.

Neurology. 2018 Nov 27;91(22):e2089-e2099. doi: 10.1212/WNL.0000000000006574. Epub 2018 Oct 26.

PMID:
30366977
14.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

15.

Immune-mediated neuropathies.

Kieseier BC, Mathey EK, Sommer C, Hartung HP.

Nat Rev Dis Primers. 2018 Oct 11;4(1):31. doi: 10.1038/s41572-018-0027-2. Review.

PMID:
30310069
16.

Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.

Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung HP, Aktas O, Albrecht P.

Mult Scler. 2018 Nov;24(13):1776-1778. doi: 10.1177/1352458518771276. Epub 2018 Oct 11.

PMID:
30307371
17.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
18.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium .

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

PMID:
30247567
19.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9942-9. [Epub ahead of print]

PMID:
30155789
20.

Efficacy of STA-MCA bypass surgery in moyamoya angiopathy: long-term follow-up of the Caucasian Krupp Hospital cohort with 81 procedures.

Kraemer M, Karakaya R, Matsushige T, Graf J, Albrecht P, Hartung HP, Berlit P, Laumer R, Diesner F.

J Neurol. 2018 Oct;265(10):2425-2433. doi: 10.1007/s00415-018-9031-4. Epub 2018 Aug 28.

PMID:
30155735

Supplemental Content

Loading ...
Support Center